CIK 0001974640
APGE Apogee Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 39 d ago. Close $135.07 on Sep 2, 2026, 0% from the 52-week low and 0% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at Apogee Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | Carl Dambkowski Chief Medical Officer sell | $103k 2,725 shares | -1% | - | |
| 5Weak | Carl Dambkowski Chief Medical Officer sell | $103k 2,725 shares | -1% | - | |
| 0Weak | Carl Dambkowski Chief Medical Officer sell | $455k 10,090 shares | -4% | - | |
| 5Weak | Carl Dambkowski Chief Medical Officer sell | $101k 2,725 shares | -1% | - | |
| 5Weak | Carl Dambkowski Chief Medical Officer sell | $97k 2,725 shares | -1% | - | |
| 6Weak | Carl Dambkowski Chief Medical Officer sell | $140k 3,860 shares | -2% | - | |
| 27Weak | Michael Thomas Henderson Chief Executive Officer sell | $302k 10,000 shares | -1% | - | |
| 10Weak | Carl Dambkowski Chief Medical Officer sell | $48k 1,590 shares | -1% | - | |
| 33Weak | Michael Thomas Henderson Chief Executive Officer sell | $609k 15,000 shares | -1% | - | |
| 0Weak | Carl Dambkowski Chief Medical Officer sell | $143k 3,520 shares | -1% | - | |
| 34Weak | Michael Thomas Henderson Chief Executive Officer sell | $733k 15,000 shares | -1% | - | |
| 0Weak | Carl Dambkowski Chief Medical Officer sell | $192k 4,085 shares | -2% | - | |
| 48Moderate | Mark C. McKenna director buy | $991k 20,000 shares | - | - | |
| 0Weak | Carl Dambkowski Chief Medical Officer sell | $221k 4,540 shares | -2% | - | |
| 34Weak | Michael Thomas Henderson Chief Executive Officer sell | $699k 15,000 shares | -1% | - | |
| 17Weak | Carl Dambkowski Chief Medical Officer sell | $307k 6,665 shares | -2% | - | |
| 36Weak | Michael Thomas Henderson Chief Executive Officer sell | $888k 15,000 shares | -1% | - | |
| 19Weak | Carl Dambkowski Chief Medical Officer sell | $394k 6,665 shares | -2% | - |
Transactions
The last 98 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Common Stockindirect: By Fairmount Healthcare Fund II LP | -340,855 | - | - | 0 | 39 d ago |
| Sep 2, 2026 | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Common Stock | -1,375 | $135.06 | $186k | 167,123 | 39 d ago |
| Sep 3, 2026 | Mark C. McKenna director | DDisposition to issuer Common Stock | -20,000 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | William A Jones Jr director | DDisposition to issuer Common Stock | -34,824 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Nimish P Shah director | DDisposition to issuer Common Stockindirect: See footnote | -1,750,000 | $135.11 | $236M | 0 | 39 d ago |
| Sep 3, 2026 | Jennifer A. Fox director | DDisposition to issuer Common Stock | -34,824 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Jane Henderson Chief Financial Officer | DDisposition to issuer Common Stock | -158,371 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,550 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Common Stock | -920,941 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Common Stockindirect: By Tomas Kiselak | -51,166 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -150,000 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | William A Jones Jr director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Common Stock | -167,123 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Jennifer A. Fox director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Jane Henderson Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -175,345 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,112 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -387,012 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Nimish P Shah director | DDisposition to issuer Non-Voting Common Stockderivativeindirect: See footnote | -6,743,321 | $135.11 | $911M | 0 | 39 d ago |
| Sep 3, 2026 | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -357,036 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Common Stockindirect: By Peter Harwin | -51,166 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | William A Jones Jr director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Jane Henderson Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -124,962 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -47,758 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Jennifer A. Fox director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,665 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -124,962 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Non-Voting Common Stockderivativeindirect: By Fairmount Healthcare Fund II LP | -6,743,321 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | William A Jones Jr director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Jennifer A. Fox director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -253,016 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Jane Henderson Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -83,690 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -83,690 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -47,758 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Nimish P Shah director | DDisposition to issuer Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnote | -365,853 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | Fairmount Funds Management LLC director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -7,657 | - | - | 0 | 39 d ago |
| Sep 3, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,535 | $37.82 | $96k | 233,738 | Sep 5, 2025 |
| Sep 3, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -190 | $38.55 | $7,325 | 233,548 | Sep 5, 2025 |
| Aug 6, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,725 | $37.78 | $103k | 236,273 | Aug 8, 2025 |
| Jul 2, 2025 | Carl Dambkowski Chief Medical Officer | MOption exercise Common Stock10b5-1 | +7,365 | $22.86 | $168k | 249,088 | Jul 3, 2025 |
| Jul 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -6,409 | $44.77 | $287k | 242,679 | Jul 3, 2025 |
| Jul 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,935 | $45.49 | $134k | 239,744 | Jul 3, 2025 |
| Jul 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -746 | $46.26 | $35k | 238,998 | Jul 3, 2025 |
| Jul 2, 2025 | Carl Dambkowski Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,365 | $0.00 | $0 | 164,010 | Jul 3, 2025 |
| Jun 17, 2025 | Lisa Bollinger director | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | Jennifer A. Fox director | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | Andrew Gottesdiener director | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | William A Jones Jr director | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | Mark C. McKenna director | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | Nimish P Shah director | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | Fairmount Funds Management LLC director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | Fairmount Funds Management LLC director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Tomas Kiselak | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 4, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,725 | $36.96 | $101k | 241,723 | Jun 6, 2025 |
| May 7, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,725 | $35.75 | $97k | 244,448 | May 9, 2025 |
| Apr 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,471 | $35.56 | $88k | 248,562 | Apr 4, 2025 |
| Apr 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -500 | $37.03 | $19k | 248,062 | Apr 4, 2025 |
| Apr 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -889 | $37.59 | $33k | 247,173 | Apr 4, 2025 |
| Mar 5, 2025 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -7,326 | $29.98 | $220k | 1,295,661 | Mar 7, 2025 |
| Mar 5, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,590 | $30.48 | $48k | 251,033 | Mar 7, 2025 |
| Mar 5, 2025 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -2,674 | $30.62 | $82k | 1,292,987 | Mar 7, 2025 |
| Feb 5, 2025 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -15,000 | $40.58 | $609k | 1,302,987 | Feb 7, 2025 |
| Feb 5, 2025 | Carl Dambkowski Chief Medical Officer | MOption exercise Common Stock10b5-1 | +795 | $22.86 | $18k | 256,143 | Feb 7, 2025 |
| Feb 5, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -3,520 | $40.69 | $143k | 252,623 | Feb 7, 2025 |
| Feb 5, 2025 | Carl Dambkowski Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -795 | $0.00 | $0 | 171,375 | Feb 7, 2025 |
| Jan 31, 2025 | Michael Thomas Henderson Chief Executive Officer | MOption exercise Common Stock | +8,500 | $22.86 | $194k | 1,317,987 | Jan 31, 2025 |
| Jan 31, 2025 | Michael Thomas Henderson Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -8,500 | $0.00 | $0 | 390,012 | Jan 31, 2025 |
| Jan 8, 2025 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -12,132 | $48.72 | $591k | 1,312,355 | Jan 10, 2025 |
| Jan 8, 2025 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -2,868 | $49.38 | $142k | 1,309,487 | Jan 10, 2025 |
| Jan 2, 2025 | Carl Dambkowski Chief Medical Officer | MOption exercise Common Stock10b5-1 | +1,360 | $22.86 | $31k | 259,433 | Jan 3, 2025 |
| Jan 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,499 | $46.42 | $70k | 257,934 | Jan 3, 2025 |
| Jan 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,486 | $47.21 | $117k | 255,448 | Jan 3, 2025 |
| Jan 2, 2025 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -100 | $47.92 | $4,792 | 255,348 | Jan 3, 2025 |
| Jan 2, 2025 | Carl Dambkowski Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,360 | $0.00 | $0 | 172,170 | Jan 3, 2025 |
| Dec 12, 2024 | Mark C. McKenna director | POpen-market purchase Common Stock | +7,500 | $49.02 | $368k | 7,500 | Dec 16, 2024 |
| Dec 12, 2024 | Mark C. McKenna director | POpen-market purchase Common Stock | +12,500 | $49.85 | $623k | 20,000 | Dec 16, 2024 |
| Dec 11, 2024 | Carl Dambkowski Chief Medical Officer | MOption exercise Common Stock10b5-1 | +1,815 | $22.86 | $41k | 262,613 | Dec 13, 2024 |
| Dec 11, 2024 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -4,085 | $48.62 | $199k | 258,528 | Dec 13, 2024 |
| Dec 11, 2024 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -455 | $50.00 | $23k | 258,073 | Dec 13, 2024 |
| Dec 11, 2024 | Carl Dambkowski Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,815 | $0.00 | $0 | 173,530 | Dec 13, 2024 |
| Dec 9, 2024 | Carl Dambkowski Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +124,962 | $0.00 | $0 | 124,962 | Dec 11, 2024 |
| Dec 9, 2024 | Jane Henderson Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +124,962 | $0.00 | $0 | 124,962 | Dec 11, 2024 |
| Dec 9, 2024 | Michael Thomas Henderson Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +357,036 | $0.00 | $0 | 357,036 | Dec 11, 2024 |
| Dec 4, 2024 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -13,328 | $46.50 | $620k | 1,326,159 | Dec 6, 2024 |
| Dec 4, 2024 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -6,665 | $46.07 | $307k | 260,798 | Dec 6, 2024 |
| Dec 4, 2024 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,672 | $47.19 | $79k | 1,324,487 | Dec 6, 2024 |
| Nov 6, 2024 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -14,000 | $59.17 | $828k | 1,340,487 | Nov 8, 2024 |
| Nov 6, 2024 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,326 | $58.91 | $314k | 268,802 | Nov 8, 2024 |
| Nov 6, 2024 | Michael Thomas Henderson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,000 | $59.94 | $60k | 1,339,487 | Nov 8, 2024 |
| Nov 6, 2024 | Carl Dambkowski Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,339 | $59.96 | $80k | 267,463 | Nov 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Lisa Bollingerdirector
- Carl DambkowskiChief Medical Officer
- Fairmount Funds Management LLCdirector, owner
- Jennifer A. Foxofficer, director
- Andrew Gottesdienerdirector
- Michael Thomas HendersonChief Executive Officer
- Jane HendersonChief Financial Officer
- William A Jones Jrdirector, officer
- Mark C. McKennadirector
- Nimish P Shahowner, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.